Nearly 70% of HIV-infected homeless or marginally housed individuals receiving tenofovir/FTC/efavirenz demonstrated virologic suppression at 6 months.
Many HIV-infected populations, including the homeless, are thought to have less than optimal treatment adherence and to therefore be at increased risk for virologic failure and antiretroviral resistance. Such populations may benefit from simpler regimens, such as the once-daily single-pill regimen consisting of tenofovir/FTC/efavirenz (Atripla), but this hypothesis has not been well studied.
In a recent observational study (partially funded by the makers of tenofovir/FTC/efavirenz), researchers evaluated rates of treatment adherence and virologic suppression among 118 homeless or marginally housed HIV-infected patients in San Francisco: 47 who received tenofovir/FTC/efavirenz and 71 who received standard regimens that have a higher pill burd…
Reviewing Authors
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)